This week’s Innovation Partners BioBlog examines two emerging trends: fewer people enrolling in the Affordable Care Act and more people choosing $0 premiums during Medicare enrollment. President Trump continues to push to mandate low drug prices while the drug makers push back. These and more are
Technology Transforms Healthcare Payment Models and Methods
This week, the Innovation Partners BioBlog looks are breaking articles on how technology can help the shift to new healthcare payment models. Voters agree that the soaring cost of drug prices should be curbed, but disagree on how to do so. CMS delayed its ruling to hospitals and healthcare providers
The Conversation about Rising Drug Prices
In this week’s Innovation Partners BioBlog, we look at many of the top stories highlighting the conversation about drug prices. Canada’s acting ambassador nixes the Trump Administration’s suggestion that Canadian drug imports will lower prices. Neulasta has another competitor as a third biosimilar
Healthcare Legislation, Drug Price Reduction, and More
In this week’s Innovation Partners BioBlog, we look at top stories impacting the world of healthcare especially those affected by politics and legislation. Senator Pelosi pushes for passage of her bill to lower drug prices but opponents believe it will stifle innovation and the development of new
FDA Generic Approvals Hit New Record, Humana Files Suit
This week in the Innovation Partners BioBlog, we look at several top stories including the record-breaking FDA approval rate for generic drugs. Human leveled serious charges against several pharmaceutical firms including Teva for price fixing, alleging up to 1,000% overcharge on some drugs including
Filling the Drug Shortfall Gap, Predicting Demand, and Saving On Medications
In this week’s Innovation Partners BioBlog, we look at several top stories from the pharmaceutical industry. Merck is testing machine learning to predict demand, a move that is expected to prevent wasteful stockpiling and expired drugs. Pfizer fills the gap left by Teva’s discontinuation of an
California Leads in New Healthcare Bills, Ripple Effects Expected
California Governor Newsom inked bill AB 824 and is expected to sign AB 744 this week, both of which will impact healthcare payment models. Companies seeking to manage healthcare costs are actively trying to influence where medications are delivered. New cancer research in triple negative breast
ESMO Conference Updates and More
The European Society of Medical Oncology (ESMO) conference wrapped up this week with many exciting announcements and developments. New studies from Lilly, AstraZeneca, Merck and others showed promise treating lung cancer, thyroid cancer, prostate cancer and more. Hospitals and medical groups are